Close
  Indian J Med Microbiol
 

Figure 1: (a) Myositis-specific and myositis-associated antibodies in the cohort (n = 128). (b) Serum fatty acid-binding protein 3 levels in active and inactive disease as defined by myositis disease activity assessment tool ≥1. (c) Serum fatty acid-binding protein 3 levels in early disease. (d) Predictive potential of fatty acid-binding protein 3 and conventional muscle biomarkers to distinguish active from inactive disease. (e) Fall in serum fatty acid-binding protein 3 levels with response to therapy

Figure 1: (a) Myositis-specific and myositis-associated antibodies in the cohort (<b>n</b> = 128). (b) Serum fatty acid-binding protein 3 levels in active and inactive disease as defined by myositis disease activity assessment tool ≥1. (c) Serum fatty acid-binding protein 3 levels in early disease. (d) Predictive potential of fatty acid-binding protein 3 and conventional muscle biomarkers to distinguish active from inactive disease. (e) Fall in serum fatty acid-binding protein 3 levels with response to therapy